Cstone Pharmaceuticals Co. Ltd., of Suzhou, China, and Blueprint Medicines Corp., of Cambridge, Mass.
Inhibitor of KIT and PDGFRA
Unresectable or metastatic gastrointestinal stromal tumors
Treated first patient in a registrational bridging study in China that includes a dose-escalation phase and a dose-expansion phase
Exopharm Ltd., of Melbourne, Australia
Exosomes from platelets
Started the Plexoval study testing safety, wound closure and scarring over 42 days after a single injection of Plexaris in up to 20 patients
The date indicated refers to the BioWorld Clinical data table in which the news item can be found.
For more information about individual companies and/or products, see Cortellis.